By evaluating the antitumor effects of multiple anti-LAT1 mAbs, one study demonstrated that a novel anti-LAT1 mAb effectively inhibited tumor development and thus, it holds promise for cancer therapy (244). This evidence concerns the gene SLC7A5 and neoplasm.